Biocon · NSE: BIOCON · BSE: 532523

Q3 FY24 results · Oct–Dec 2023

Biocon reported revenue from operations of ₹3,953.70 crore (up 34.4% from Q3 FY23) and net profit of ₹753.30 crore for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY24	Q3 FY23	YoY	Q2 FY24	QoQ
Revenue from operations	3,953.70	2,941.10	+34.4%	3,462.30	+14.2%
Other income	565.50	78.60	+619.5%	157.90	+258.1%
Total income	4,519.20	3,019.70	+49.7%	3,620.20	+24.8%
Profit before share of associates & JVs and tax	832.30	30.10	28x	238.50	+249.0%
Share of profit/(loss) of associates & JVs	(24.10)	(55.60)		(24.20)
Net profit for the period	753.30	(20.70)	Turned profit	172.70	+336.2%
Attributable to shareholders of the company	660.00	(41.80)	Turned profit	125.60	+425.5%
EPS, basic (₹)	5.52	(0.35)	Turned profit	1.05	+425.7%
Net margin (%)	19.1	-0.7		5.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY24	Q3 FY23	YoY	Q2 FY24	QoQ
Revenue from operations	562.80	555.00	+1.4%	518.70	+8.5%
Other income	48.50	59.90	−19.0%	69.60	−30.3%
Total income	611.30	614.90	−0.6%	588.30	+3.9%
Profit before tax	32.90	46.50	−29.2%	46.00	−28.5%
Net profit for the period	24.00	35.20	−31.8%	34.70	−30.8%
EPS, basic (₹)	0.20	0.29	−31.0%	0.29	−31.0%
Net margin (%)	4.3	6.3		6.7

Consolidated

Filed with BSE: 10 Feb 2024, 11:52 IST
Board meeting: 08 Feb 2024
Period: 01 Oct 2023 to 31 Dec 2023
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 10 Feb 2024, 11:52 IST
Board meeting: 08 Feb 2024
Period: 01 Oct 2023 to 31 Dec 2023
Review status: Unaudited
Source: XBRL filing on BSE